The achievements achieved by the clinical pharmacological team of School of Pharmacy, Nanchang University won the Second Prize of National S

The Xie Mingyong’s team of our university won the Second Prize of National Science and Technology Progress Award as the first unit, and the “construction of rosuvastatin calcium and its preparations industrialized preparation system and the reasonable clinical application” participated in by the clinical pharmacological team of School of Pharmacy won the Second Prize of National Science and Technology Progress Award.

　　The achievements were mainly completed by Lunan Beite Pharmaceutical Co., Ltd., Nanchang University, Shandong New Times Pharmaceutical Co., Ltd., and Lunan Pharmaceutical Group Co., Ltd. The winning team members included: Zhang Guimin, Zhang Lixing, Xia Chunhua (Nanchang University), Zhang Zeping, Xiong Yuqin (Nanchang University), Zhao Zhiquan, Feng Zhong, Huang Wenbo, Hao Guizhou, and Wang Benli.

　　The clinical pharmacological team lead by Professor Xiong Yuqin and Professor Xia Chunhua has been long engaged in the studies on the key technology in original new drugs and the mechanism of accurate clinical medications. By relying on the scientific research platforms such as Clinical Pharmacology Institute of Nanchang University and Jiangxi Province Clinical Drug Metabolism Kinetics Key Laboratory and the active cooperation with units such as Lunan Beite Pharmaceutical Co., Ltd., they carried out the first systematic study on the clinical pharmacokinetic characteristics of the new drug rosuvastatin calcium among the Chinese population and the race-related differences in clinical administration; the finding was that there was a significant difference between the Chinese population and the Caucasians in terms of the pharmacokinetic process of the new drug, and they propose that 5 mg should be the administered dose applicable to the Chinese population (the initial dose for Caucasians should be 20 mg). Based on the aforementioned findings, they carried out a deep investigation on the in vivo pharmacokinetic characteristics of new statins including rosuvastatin calcium among the Chinese population and the inherent link with genetic polymorphism, and proposed that the OATP1B1 site 521T→C mutation was a key factor that impacted the clinical efficacy and safety of rosuvastatin calcium preparations This research result effectively supports the commercial availability of 7 new drugs of rosuvastatin calcium and its tablets (5 mg, 10 mg and 20 mg) and dispersible tablets in China, and the sales amount of the 5 mg strength which most suits the Chinese population accounts for over 80% of the domestic market, generating remarkable economic effects and social benefits.

　　As is reported, there were 171 prizes in National Science and Technology Progress Award in 2016, 4 of which were related with drug and biomedicine engineering. This award is a breakthrough of our university in the field of pharmacy by winning a National Science and Technology Award, and also the only prize within our province in the medical field. It will play an important guiding and demonstrating role in boosting the development of the provincial medical and pharmaceutical development, consolidating the industry, teaching and research cooperation, and promoting the provincial innovative drug R&D.